 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...5253545556575859606162...6970» |
- Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg.
Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2033;
P2
Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) is safe and demonstrated modest activity in H-resistant HER2-positive (HER2+) metastatic breast cancer...Moreover, the synergy of H and K with paclitaxel (T) may overcome the need for dual HER2-blockade with H plus pertuzumab (P)...Legal entity responsible for the study: The authors. Funding: Breast Cancer Research Foundation, Merck & Co.
- Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2032;
P2
Legal entity responsible for the study: International Breast Cancer Study Group. Funding: Pfizer, Roche.
- Perjeta (pertuzumab) / Roche
Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1999;
T6 may be considered a therapeutic option in low budget scenarios for patients HR+/N-. Legal entity responsible for the study: The authors.
- Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Perjeta (pertuzumab) / Roche
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1953;
Our results showed that the selection of chemotherapy that will be associated with the dual blockade of HER2 is of paramount importance in order to avoid severe toxicities and increase the compliance with treatment. Legal entity responsible for the study: Department of Oncology, Belcolle Hospital.
- Herceptin (trastuzumab) / Roche
The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment: Single center experience in setting of no reimbursement in Poland (2011-2015) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1943;
Prognosis in HER2-positive breast cancer in the analysed subgroup of Polish patients was poorer than in TNBC. The results underline the importance of treatment according to international guidelines and speak in favour of including anti-HER2 therapy preoperatively.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Journal: Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. (Pubmed Central) - Sep 11, 2019
The results underline the importance of treatment according to international guidelines and speak in favour of including anti-HER2 therapy preoperatively. These results demonstrate that HP-containing regimens yield higher pCR rates compared with H-containing regimens in patients with stage II to III HER2 BC in clinical practice regardless of chemotherapy backbone.
- | Tykerb (lapatinib) / Novartis, Perjeta (pertuzumab) / Roche
Review, Journal: Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. (Pubmed Central) - Sep 10, 2019
However, only a few of them have been validated in clinical series; moreover, in the era of standard-of-care dual HER2 blockade, these mechanisms should be re-assessed and, in case, confirmed with anti-HER2 combinations. Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy.
- | Herceptin (trastuzumab) / Roche
Journal: Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin. (Pubmed Central) - Sep 7, 2019
The husFv-immunoapoptotins demonstrated improved HER2-targeting and tumor-killing capacities in vitro and in vivo compared with the e23sFv-immunoapoptotins and would enable the administration of multiple treatment cycles to patients, resulting in improved antitumor efficacy. Furthermore, the husFvs recognized distinct HER2 epitopes and could thus be used in combination with trastuzumab or pertuzumab to achieve robust synergistic antitumor effects in HER2-positive malignancies.
- | paclitaxel / Generic Mfg.
Journal: Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer. (Pubmed Central) - Sep 7, 2019
Inhibition of either ERBB2 or ERBB3 alone did not completely shut down downstream signaling of ERBB2 and ERBB3; however, inhibition of both ERBB2 and ERBB3 blocked downstream signaling activated by SLC3A2-NRG1 fusion. ERBB2 and ERBB3 might be promising targets for treatment of SLC3A2-NRG1-positive tumors.
- ||||| Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Perjeta (pertuzumab) / Roche
Clinical, BRCA Biomarker, PARP Biomarker: Case based discussions and the students found all the answers! #vonhippellindau & VEGF inhibitors, nivo for melanoma, trastuzumab/pertuzumab for HER2+ breast, AR antagonists for prostate, PARP inhibitors for BRCA mutated. All the hallmarks & how we treat #beyondchemo. (Twitter) - Sep 6, 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Enrollment change, Trial completion date: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Sep 6, 2019
P1, N=26, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
ERBB2 and ERBB3 might be promising targets for treatment of SLC3A2-NRG1-positive tumors. Active, not recruiting --> Completed | N=40 --> 26 | Trial completion date: Mar 2019 --> Dec 2018
- | Herceptin (trastuzumab) / Roche
Clinical, Clinical guideline, Journal: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (Pubmed Central) - Sep 1, 2019
Neratinib causes substantial diarrhea, and diarrhea prophylaxis must be used. Additional information can be found at www.asco.org/breast-cancer-guidelines .
- | doxorubicin hydrochloride / generics
Clinical, Journal: Usefulness of Global Longitudinal Strain for Early Identification of Subclinical Left Ventricular Dysfunction in Patients With Active Cancer. (Pubmed Central) - Aug 30, 2019
In conclusion, our study demonstrates that GLS reduction is frequent in active cancer patients, precedes LVEF reduction and cannot be anticipated by other echocardiographic parameters. Using GLS routinely during therapy may lead to an early diagnosis of cardiotoxicity.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Aug 29, 2019
P2, N=377, Active, not recruiting, Sponsor: MedSIR
Using GLS routinely during therapy may lead to an early diagnosis of cardiotoxicity. Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche
Journal, Tumor Mutational Burden, MSi-H Biomarker: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. (Pubmed Central) - Aug 28, 2019
The success of anti-HER2 therapies in ongoing clinical trials is a promising development for patients with CRC. Cancer 2018.
- | Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=5, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Cancer 2018. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
- |||| Tykerb (lapatinib) / Novartis, Perjeta (pertuzumab) / Roche
Clinical: Patients were naive to T-DM1, also was a exclusion criteria. All patients received earlier #trastuzumab, 46 % received earlier #pertuzumab and 20 % received earlier #lapatinib. @prat_aleix @JAMAOnc @FAndreMD https://t.co/PeyWjBLDdH (Twitter) - Aug 25, 2019
- | Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. (Pubmed Central) - Aug 21, 2019
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2019 Molecular analysis and personalized therapy can help optimize treatment in difficult-to-treat cancers.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Aug 15, 2019
P2, N=70, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Molecular analysis and personalized therapy can help optimize treatment in difficult-to-treat cancers. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Aug 2019 | Trial primary completion date: Jan 2020 --> Aug 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Combination therapy, PD(L)-1 Biomarker, IO biomarker: IMpassion050: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (clinicaltrials.gov) - Aug 14, 2019
P3, N=453, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Aug 2019 | Trial primary completion date: Jan 2020 --> Aug 2019 N=224 --> 453
- | Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial (clinicaltrials.gov) - Aug 11, 2019
P3, N=250, Recruiting, Sponsor: Hoffmann-La Roche
N=224 --> 453 Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025
- | Perjeta (pertuzumab) / Roche
Clinical, Journal, Combination therapy: A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel. (Pubmed Central) - Aug 11, 2019
Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025 This work shows that PK-toxicity modeling provides insight into how the severity of key adverse events evolves over time and highlights the potential use to support decision making in drug development.
- | Perjeta (pertuzumab) / Roche
Journal: Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. (Pubmed Central) - Aug 9, 2019
Therefore, we concluded that this single radiolabeled tracer can provide all-in-one contrast for multiple imaging modalities. The dual-labeled mAbs may hold promise to be employed for image-guided tumor surgery as well as diagnosis and staging through balancing out the strengths and weaknesses of various modalities such as PET/CT, NIRF, CL, and β particle imaging.
- | Herceptin (trastuzumab) / Roche
Clinical, P2a data, Journal: Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. (Pubmed Central) - Aug 3, 2019
P2a
Tumor-pathway cohorts with notable objective response rates included human epidermal growth factor receptor-2-amplified/overexpressing colorectal (38% [14 of 37]; 95% CI, 23% to 55%) and v-raf murine sarcoma viral oncogene homolog B1 V600-mutated non-small-cell lung cancer (43% [six of 14]; 95% CI, 18% to 71%). Conclusion The four currently approved targeted therapy regimens in the MyPathway study produced meaningful responses when administered without chemotherapy in several refractory solid tumor types not currently labeled for these agents.
- | Herceptin (trastuzumab) / Roche
Review, Journal: HER2: An emerging target in colorectal cancer. (Pubmed Central) - Aug 3, 2019
This review presents an overview of epidermal growth factor receptor and HER2 pathways in CRC and discusses preclinical and clinical studies carried out in this field to date. There is potential that with continued evolution of data in this area, HER2 may become a validated therapeutic target and thus, anti-HER2 therapy may become an additional treatment option for a small population of patients with metastatic CRC.
- | Perjeta (pertuzumab) / Roche
Journal: Functional characterization of two variants in the 3'-untranslated region (UTR) of transcription factor 4 gene and their association with schizophrenia in sib-pairs from multiplex families. (Pubmed Central) - Aug 1, 2019
However, only the C allele of rs1272363 reduced the luciferase activity significantly (p = 0.0231). Our results suggested that rs1273263 is a potential regulator of TCF4 expression, and might be associated with schizophrenia.
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date: NA-PHER2: "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " (clinicaltrials.gov) - Aug 1, 2019
P2, N=102, Active, not recruiting, Sponsor: Fondazione Michelangelo
Our results suggested that rs1273263 is a potential regulator of TCF4 expression, and might be associated with schizophrenia. Trial primary completion date: Mar 2019 --> Sep 2019
- ||| Perjeta (pertuzumab) / Roche
13/ pCR-incr: In #bcsm we feel a little burned as that’s what we thought as well & monoclonal antibodies would sure change this lack of surrogacy...Pertuzumab: great pCR-incr ~20%, but nearly failed again (except in LN+ very limited benefit in EFS). Let’s hope #IO better... (Twitter) - Jul 29, 2019
- | paclitaxel / Generic mfg., docetaxel / Generic mfg.
Enrollment open: Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (clinicaltrials.gov) - Jul 28, 2019
P2, N=240, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Trial primary completion date: Mar 2019 --> Sep 2019 Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Jul 25, 2019
P1, N=100, Recruiting, Sponsor: Pravin Kaumaya
Not yet recruiting --> Recruiting N=36 --> 100
- | paclitaxel / generics
Journal, Combination therapy: Mechanistic Investigations of Diarrhea Toxicity Induced by anti-HER2/3 Combination Therapy. (Pubmed Central) - Jul 24, 2019
Our in vitro investigations showed that pertuzumab and lumretuzumab combination treatment resulted in up-regulation of chloride channel activity without indication of intestinal barrier disruption. Overall, our findings provide a mechanistic rationale to explore alternative of conventional anti-gut motility using medication targeting chloride channel activity to mitigate diarrhea of HER combination therapies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Jul 22, 2019
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Overall, our findings provide a mechanistic rationale to explore alternative of conventional anti-gut motility using medication targeting chloride channel activity to mitigate diarrhea of HER combination therapies. Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy. (Pubmed Central) - Jul 19, 2019
Cetuximab-pertuzumab with 10 Gy photon irradiation switched off both phospho-AKT and phospho-MEK1/2 expression in the three populations. The triple therapy is therefore thought to inhibit SQ20B cells, SQ20B-CSCs and FaDu cells through an AKT-mTOR and Ras-MAPK downstream signalling blockade.
- ||| Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Great to discuss early #her2 positive breast cancer with @EdithPerezMD and Maire Patterson #pertuzumab #TDM1 #neratinib #bcsm (Twitter) - Jul 18, 2019
- | Biomarker, Enrollment closed, Trial completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 18, 2019
P2, N=1400, Active, not recruiting, Sponsor: Hoffmann-La Roche
The triple therapy is therefore thought to inhibit SQ20B cells, SQ20B-CSCs and FaDu cells through an AKT-mTOR and Ras-MAPK downstream signalling blockade. Suspended --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2020
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. (Pubmed Central) - Jul 17, 2019
An increase in regulatory T cells in non-pCR tissues suggests the development of an immunosuppressive phenotype. Further investigation in a larger cohort of samples is warranted to validate these findings.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Jul 16, 2019
P3, N=780, Active, not recruiting, Sponsor: Hoffmann-La Roche
Further investigation in a larger cohort of samples is warranted to validate these findings. Trial completion date: Jun 2019 --> Oct 2019
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer. (Pubmed Central) - Jul 13, 2019
Thus, there is an urgent need to develop new, innovative approaches in those patients whose disease has become resistant to these highly potent drugs. Several new antibody-drug conjugates, bispecific antibodies or new generation tyrosine kinase inhibitor (TKIs) hold promise and should be assessed and compared with drugs currently used.
- | Biomarker, Journal: Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. (Pubmed Central) - Jul 13, 2019
The biodistribution data were confirmed by SPECT/CT imaging. In conclusion, radioiodine is a preferable label for DARPin 9_29.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
.@StephenPHansen looks at how @ZymeworksInc is taking aim at @Roche $10B HER2 franchise, #Herceptin and #Perjeta https://t.co/lC3YT9LmZU (Twitter) - Jul 11, 2019
- | Clinical, P2 data, Journal, Heterogeneity: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. (Pubmed Central) - Jul 6, 2019
In conclusion, radioiodine is a preferable label for DARPin 9_29. No abstract available
- || Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jul 5, 2019
P1b, N=198, Recruiting, Sponsor: Eli Lilly and Company
No abstract available Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Mar 2020
- || Trial primary completion date, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Jul 5, 2019
P1, N=98, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Mar 2020 Trial primary completion date: Mar 2019 --> Aug 2019
- | Perjeta (pertuzumab) / Roche
Clinical, Journal: Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. (Pubmed Central) - Jul 5, 2019
These engineered pertuzumab variants show increased lysosomal delivery and cytotoxicity towards tumor cells expressing intermediate HER2 levels. In HER2 xenograft tumor models in mice, the variants show higher therapeutic efficacy than the parent ADC and a clinically approved HER2-specific ADC.
- | Herceptin (trastuzumab) / Roche
Clinical, Clinical data, P3 data, Journal: Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. (Pubmed Central) - Jul 4, 2019
P3
The addition of pertuzumab to trastuzumab improved clinical outcomes versus trastuzumab plus placebo, regardless of D treatment duration. ClinicalTrials.gov identifier: NCT00567190.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Use of pertuzumab and trastuzumab during pregnancy. (Pubmed Central) - Jun 30, 2019
Concomitant use of pertuzumab and trastuzumab during pregnancy may be associated with an unresolved oligohydramnios and/or anhydramnios risk. Extreme caution should be used when these monoclonal antibodies are administered during pregnancy.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Clinical, P3 data, Journal: Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. (Pubmed Central) - Jun 27, 2019
Extreme caution should be used when these monoclonal antibodies are administered during pregnancy. Following publication of the original article [1], the authors reported the following errors in the article.
- | paclitaxel / Generic mfg., docetaxel / Generic mfg.
New P2 trial: Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (clinicaltrials.gov) - Jun 27, 2019
P2, N=240, Not yet recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
- ||| Herceptin (trastuzumab) / Roche, margetuximab (MGAH 22) / MacroGenics, Perjeta (pertuzumab) / Roche
Clinical: Margetuximab a possible future option in patients not responding to pertuzumab/trastuzumab in MBC #LOPEE #ASCO19 @bopacommittee (Twitter) - Jun 26, 2019
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Biomarker, Journal, IO Biomarker: Use of immunotherapy to treat metastatic breast cancer. (Pubmed Central) - Jun 26, 2019
In the remaining studies, results were disappointing. In the future, finding new predictive biomarkers and exploring more suitable synergizing combinations, time and dose-dependent-scheduled sequences of currently and further investigated immunological approaches are main challenges.